Detrick B, Nagineni C N, Grillone L R, Anderson K P, Henry S P, Hooks J J
. The Department of Pathology, The Johns Hopkins Medical Institutes, Baltimore, Maryland, USA.
Invest Ophthalmol Vis Sci. 2001 Jan;42(1):163-9.
The antiviral activity of first and second generation antisense oligonucleotides on human cytomegalovirus (CMV) replication was evaluated in two cell systems, the traditional system on human fibroblasts and on human retinal pigment epithelial (HRPE) cell culture system.
To evaluate CMV replication strategies within the retina, an HRPE cell system permissive to CMV replication was developed. In this study, the antiviral activity of the antisense oligonucleotides, ISIS 2922 (Vitraven) and ISIS 13312, was evaluated in the traditional fibroblast antiviral assay and in the HRPE cell system. Antiviral activity was measured by evaluating inhibition of virus induced cytopathic effect, virus plaque formation, and virus gene expression.
Both oligonucleotides produced concentration-dependent inhibition of CMV cytopathic effect and CMV plaque formation in both human RPE cells and a human fibroblast cell line, MRC-5. The oligonucleotide, ISIS 2922, demonstrated a mean 50% inhibitory concentration (IC(50)) of 0.04 and 0.24 microM in HRPE and MRC-5 cells, respectively. The second-generation oligonucleotide, ISIS 13312, yielded similar results with IC(50) levels of 0.05 and 0.3 microM in HRPE and MRC-5 cells, respectively. Similar findings were obtained with a CMV clinical isolate. In addition, initiation of effective oligonucleotide treatment could be introduced 6 days after CMV infection in HRPE cells, whereas, in the fibroblast cell line, oligonucleotide treatment was only effective up to 3 days after infection. Semiquantitative RT-PCR analysis demonstrated significant inhibition of CMV intermediate early and late mRNAs by both oligonucleotides.
These studies demonstrate that HRPE cells were significantly more sensitive than fibroblasts to the antiviral actions of ISIS 2922 and ISIS 13312. Moreover, the data indicate that the anti-CMV potency of the two oligonucleotides was similar. The enhanced potency of these oligonucleotides in HRPE cells may be associated with a delay in viral gene transcription and slow viral replication and spread in these cells.
在两种细胞系统中评估第一代和第二代反义寡核苷酸对人巨细胞病毒(CMV)复制的抗病毒活性,这两种细胞系统分别是传统的人成纤维细胞系统和人视网膜色素上皮(HRPE)细胞培养系统。
为了评估视网膜内的CMV复制策略,开发了一种允许CMV复制的HRPE细胞系统。在本研究中,在传统的成纤维细胞抗病毒试验和HRPE细胞系统中评估了反义寡核苷酸ISIS 2922(Vitraven)和ISIS 13312的抗病毒活性。通过评估对病毒诱导的细胞病变效应、病毒空斑形成和病毒基因表达的抑制来测量抗病毒活性。
两种寡核苷酸在人RPE细胞和人成纤维细胞系MRC-5中均产生了浓度依赖性的对CMV细胞病变效应和CMV空斑形成的抑制。寡核苷酸ISIS 2922在HRPE细胞和MRC-5细胞中的平均50%抑制浓度(IC50)分别为0.04和0.24 microM。第二代寡核苷酸ISIS 13312在HRPE细胞和MRC-5细胞中的IC50水平分别为0.05和0.3 microM,结果相似。使用CMV临床分离株也获得了类似的结果。此外,在HRPE细胞中,CMV感染后6天开始进行有效的寡核苷酸治疗仍有效,而在成纤维细胞系中,寡核苷酸治疗仅在感染后3天内有效。半定量RT-PCR分析表明,两种寡核苷酸均显著抑制CMV早期和晚期中间mRNA。
这些研究表明,HRPE细胞对ISIS 2922和ISIS 13312的抗病毒作用比成纤维细胞敏感得多。此外,数据表明这两种寡核苷酸的抗CMV效力相似。这些寡核苷酸在HRPE细胞中效力增强可能与病毒基因转录延迟以及这些细胞中病毒复制和传播缓慢有关。